[1] Porras C, Nodora J, Sexton R,et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)[J].Cancer Causes Control,2013,24(2):209-215. [2] Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption[J].Gut,2013,62(1):34-42. [3] Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis[J].Exp Ther Med,2015,9(3):707-716. [4] Patel A, Shah N, Prajapati JB. Clinical application of probiotics in the treatment of Helicobacter pylori infection--a brief review[J].J Microbiol Immunol Infect,2014,47(5):429-437. [5] 张咏华,张锋,张欣,等.三联疗法治疗消化性溃疡的临床分析及预后分析[J].湖南师范大学学报(医学版),2015,(5):83-85. [6] 徐燕,张杰.两种三联疗法根除幽门螺杆菌感染胃溃疡临床疗效比较[J].中国实用医药,2014,9(24):12-13. [7] 黄久评,曾庆彩.艾普拉唑联合铋剂标准四联与序贯方案治疗幽门螺杆菌感染性慢性胃炎的疗效比较[J].医学临床研究,2015.32(2):380-382. [8] 李锐强,胡宝英.含铋剂的四联疗法与标准三联疗法对幽门螺杆菌相关性消化性溃疡的疗效对比[J].临床消化病杂志,2015,27(6):327-329. [9] 黄光俊.含铋剂四联与标准三联疗法根除幽门螺杆菌疗效对比分析[J].咸宁学院学报(医学版),2012,26(4):304-305. [10] 孔聪聪,刘改芳,吴婧,等.同铋剂四联疗法根除幽门螺杆菌240例的疗效分析[J].中华消化杂志,2014,34(8):513-515.
2019, Vol. 36 
